|Articles|August 10, 2010

EGA Talks Biosimilars

The European Generic Medicines Association's Director for Scientific Affairs, Suzette Cox, talks to us about the environment for biosimilars.

Click here.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Trending on PharmExec

EGA Talks Biosimilars

Related Content

Elicio Therapeutics’ Shares Drop Following Announcement of Phase II Trial Results

Finding the Data for Rare, Pediatric Therapies: Q&A with Lisa Bollinger

Novavax's Strategy Across Commercial, R&D, and Partnerships

Partnering in Non-Opioids: Q&A with Dr. Edward Littler and Dave Watson

The ROI of Smarter Trials: Q&A with Raj Indupuri

Trending on PharmExec

Elicio Therapeutics’ Shares Drop Following Announcement of Phase II Trial Results

Partnering in Non-Opioids: Q&A with Dr. Edward Littler and Dave Watson

Novavax's Strategy Across Commercial, R&D, and Partnerships

Pharma Roundup: FDA Approves Truqap Plus Abiraterone and Prednisone, FDA Approves Keytruda and Keytruda Qlex Each in Combination with Welireg

Pharmaceutical Executive Daily: FDA Approves Two Indications of Keytruda in Combination with Welireg